Last reviewed · How we verify

Zoledronic acid 5mg

Novartis Pharmaceuticals · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Zoledronic acid 5mg is a Small molecule drug developed by Novartis Pharmaceuticals. It is currently FDA-approved. Also known as: aclasta.

Zoledronic acid 5mg is used to treat conditions such as postmenopausal osteoporosis, postmenopausal osteopenia, primary osteoporosis, osteoporosis, and osteogenesis imperfecta. It works by inhibiting farnesyl diphosphate synthase, a small molecule inhibitor of the enzyme farnesyl pyrophosphate synthase.

At a glance

Generic nameZoledronic acid 5mg
Also known asaclasta
SponsorNovartis Pharmaceuticals
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zoledronic acid 5mg

What is Zoledronic acid 5mg?

Zoledronic acid 5mg is a Small molecule drug developed by Novartis Pharmaceuticals.

Who makes Zoledronic acid 5mg?

Zoledronic acid 5mg is developed and marketed by Novartis Pharmaceuticals (see full Novartis Pharmaceuticals pipeline at /company/novartis-pharmaceuticals).

Is Zoledronic acid 5mg also known as anything else?

Zoledronic acid 5mg is also known as aclasta.

What development phase is Zoledronic acid 5mg in?

Zoledronic acid 5mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing